Cargando…

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is one of the highest fatality rate cancers with poor survival rates. The tumor microenvironment (TME) is vital for tumor immune responses, leading to resistance to chemotherapy and poor prognosis of PDAC patients. This study aimed to provide a compre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Weijia, Yan, Liang, Guan, Xiaoya, Dong, Bin, Zhao, Min, Wu, Jianhui, Tian, Xiuyun, Hao, Chunyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945593/ https://www.ncbi.nlm.nih.gov/pubmed/33718118 http://dx.doi.org/10.3389/fonc.2020.618215

Ejemplares similares

Identification of the γ-glutamyl cycle as a novel therapeutic target and 5-oxoproline as a new biomarker for diagnosing pancreatic cancer
por: Wang, Weijia, et al.
Publicado: (2023)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma
por: Fang, Lishan, et al.
Publicado: (2023)

Tumor-Infiltrating Immune Cell Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic Ductal Adenocarcinoma
por: Gao, Yuzhen, et al.
Publicado: (2020)

CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors
por: Yan, Liang, et al.
Publicado: (2020)

Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma
por: Huang, Xinyang, et al.
Publicado: (2022)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes
por: Liu, Rong, et al.
Publicado: (2021)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Development and validation of an MRI-radiomics nomogram for the prognosis of pancreatic ductal adenocarcinoma
por: Xu, Xinsen, et al.
Publicado: (2023)

Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma
por: Cui, Lixuan, et al.
Publicado: (2021)

Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma
por: Yang, Chengkun, et al.
Publicado: (2019)

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma
por: d’Engremont, Christelle, et al.
Publicado: (2021)

Computed Tomography-Based Radiomics Signature for the Preoperative Differentiation of Pancreatic Adenosquamous Carcinoma From Pancreatic Ductal Adenocarcinoma
por: Ren, Shuai, et al.
Publicado: (2020)

Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
por: Peng, Wenguang, et al.
Publicado: (2023)

A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma
por: Zhou, Chenhao, et al.
Publicado: (2019)

The value of enhanced CT features and texture-signatures in assessing the inflammatory infiltration of pancreatic ductal adenocarcinoma
por: Wang, Fangqing, et al.
Publicado: (2023)

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

PTK7 overexpression in colorectal tumors: Clinicopathological correlation and prognosis relevance
por: Tian, Xiuyun, et al.
Publicado: (2016)

Comprehensive immune characterization and T‐cell receptor repertoire heterogeneity of retroperitoneal liposarcoma
por: Yan, Liang, et al.
Publicado: (2019)

Loss of Cadherin-11 in pancreatic ductal adenocarcinoma alters tumor-immune microenvironment
por: Sebastian, Aimy, et al.
Publicado: (2023)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Non-coding RNAs in Pancreatic Ductal Adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Development and Validation of a Nomogram Based on Nutritional Indicators and Tumor Markers for Prognosis Prediction of Pancreatic Ductal Adenocarcinoma
por: Li, Haoran, et al.
Publicado: (2021)

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
por: Li, Ruiyu, et al.
Publicado: (2021)

A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2019)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

Large-Section Histopathology Can Better Indicate the Immune Microenvironment and Predict the Prognosis of Pancreatic Ductal Adenocarcinoma Than Small-Section Histopathology
por: Ding, Guiling, et al.
Publicado: (2021)

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
por: Wang, Yizhi, et al.
Publicado: (2020)

Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications
por: Angstadt, Shantel, et al.
Publicado: (2022)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
por: Zhang, Jingchang, et al.
Publicado: (2022)

Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma
por: Bao, Jingpiao, et al.
Publicado: (2022)

Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma
por: Liu, Hailiang, et al.
Publicado: (2020)

Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence
por: Zhang, Sha, et al.
Publicado: (2020)

T cell receptor β‐chain repertoire analysis of tumor‐infiltrating lymphocytes in pancreatic cancer
por: Cui, Can, et al.
Publicado: (2018)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer Locations
por: Li, Ge, et al.
Publicado: (2021)

Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma
por: Hashimoto, Ari, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l2m6ef3voctpb25c8kt6sipk77